BioPharmX (BPMX) Reports Q1 Loss of $0.08/Share, Explores Funding Alternatives

BioPharmX (NYSE: BPMX) reported Q1 EPS of ($0.08), versus ($0.17) reported last year.

The company expects the phase 3 program to begin later this year and is exploring a variety of funding alternatives, including both dilutive and non-dilutive financing options and strategic partnerships.

For earnings history and earnings-related data on BioPharmX (BPMX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M